

Corbus Pharmaceuticals Holdings, Inc. (CRBP)

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001595097

Corbus Pharmaceuticals Holdings, Inc. CRBP; healthcare		
Grade	None 6 of 14 inputs computable; 7 are required	Share price, twelve months to the rescan split-adjusted close; the letter is fixed at the rescan that set it 
Reliability	0.87 AUC filers with \$120M to \$591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025	
Peer failure rate	1.03% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025	
Size band	\$120M to \$591M assets total assets \$168.2M	
Standard universe	outside revenue above \$1M and assets above \$10M	
Warnings	dilution, short runway, thin data, degenerate inputs	
Inputs computable	6 of 14	
Graded from	filings received through Mar 9, 2026 214 days before the rescan; latest periodic filing 10-Q received Aug 6, 2026	
Last close	\$5.25 2026-10-08; market equity \$101.6M	
Price used in grade	None	

Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only

A	
B	
C	
D	
E	
	2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026

Business, in the company's words

opening of Item 1 of the 10-K received Mar 9, 2026

All references in this report to "Corbus," the "Company," "we," "us," or "our" mean Corbus Pharmaceuticals Holdings, Inc. and its subsidiaries unless we state otherwise, or the context otherwise indicates. Corbus Pharmaceuticals Holdings, Inc. (the "Company" or "Corbus") is a clinical stage company focused on promising new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways.

The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 45.3						
Gross profitability		not computable	32.2%		one or more required annual facts are missing	

Return on invested capital		not computable	9.3%			one or more required annual facts are missing
Accruals ratio		(8.7%)	(6.6%)	45.3	811	2025-12-31
Gross margin stability, five years		not computable	2.8 pts			five annual gross margins are required; found 0
Solvency, sleeve percentile 47.1						
Twelve-month failure probability		0.34%	0.07%	78.1	248	2026-06-30
Altman Z double-prime		(0.98)	(0.31)	41.2	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			EBITDA must exceed \$100,000 interest expense must exceed \$100,000
Interest coverage		not computable	(4.51x)			
Current ratio		8.07x	2.96x	22.1	839	2025-12-31
Growth and financing, sleeve percentile 43.8						
Revenue growth, three-year compound		not computable	10.0%			current value must be positive and the base must exceed \$100,000
Free cash flow growth, three-year compound		not computable	10.9%			four consecutive annual FCF observations are required; found 11
Reinvestment rate		not computable	37.1%			one or more required annual facts are missing
Asset growth, three years		36.4%	2.1%	12.8	704	2025-12-31
Net share issuance, one year		45.0%	2.5%	74.9	634	2026-03-06

Warnings

4 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 45.0%
Short runway	cash runway is 3.2 months
Thin data	6 of 14 grade factors are computable; minimum is 7
Degenerate inputs	latest revenue or assets are at or below the \$100,000 validity floor

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(13.8%)	8.0%	36
Distance from 52-week high	(72.8%)	(31.4%)	11
EBIT to enterprise value	(88.4%)	(1.5%)	8
Free cash flow yield	(63.3%)	(1.0%)	9
Book value to price	1.00	0.28	86

Sales to price	0.00	0.31	0
Composite equity issuance, five years	153.6%	20.3%	86
Relative strength against the sector, log excess return	(0.36)	(0.14)	36

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	\$23.4M
Operating cash flow, four quarters	-\$86.7M
Months of runway	3.2
Days since last periodic filing	64 (10-Q received Aug 6, 2026)
Median daily dollar volume, 63 sessions	\$4.4M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-\$78.5M	2025-12-31	2026-03-09	10-K	0001193125-26-098530
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$64.5M	2025-12-31	2026-03-09	10-K	0001193125-26-098530
3	assets	us-gaap:Assets	\$168.2M	2025-12-31	2026-03-09	10-K	0001193125-26-098530
4	assets	us-gaap:Assets	\$155.9M	2024-12-31	2026-03-09	10-K	0001193125-26-098530
5	current assets	us-gaap:AssetsCurrent	\$167.0M	2025-12-31	2026-03-09	10-K	0001193125-26-098530
6	current liabilities	us-gaap:LiabilitiesCurrent	\$20.7M	2025-12-31	2026-03-09	10-K	0001193125-26-098530
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$555.4M	2025-12-31	2026-03-09	10-K	0001193125-26-098530
8	operating income	us-gaap:OperatingIncomeLoss	-\$85.3M	2025-12-31	2026-03-09	10-K	0001193125-26-098530
9	book equity	us-gaap:StockholdersEquity	\$147.5M	2025-12-31	2026-03-09	10-K	0001193125-26-098530
10	liabilities	us-gaap:Liabilities	\$20.7M	2025-12-31	2026-03-09	10-K	0001193125-26-098530
11	total debt	us-gaap:LongTermDebt	\$17.9M	2023-12-31	2024-03-12	10-K	0000950170-24-030133
12	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$13.7M	2023-12-31	2025-03-11	10-K	0000950170-25-037335
13	operating income	us-gaap:OperatingIncomeLoss	-\$45.1M	2023-12-31	2025-03-11	10-K	0000950170-25-037335
14	depreciation amortization	us-gaap:Depreciation	\$600,000	2023-12-31	2025-03-11	10-K	0000950170-25-037335
15	operating income	us-gaap:OperatingIncomeLoss	-\$8.9M	2015-12-31	2018-03-12	10-K	0001493152-18-003208
16	interest expense	us-gaap:InterestExpense	\$2,440	2015-12-31	2016-03-28	10-K	0001564590-16-015403
17	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$0	2022-12-31	2023-03-07	10-K	0000950170-23-006469
18	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$881,705	2021-12-31	2023-03-07	10-K	0000950170-23-006469
19	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$3.9M	2020-12-31	2022-03-08	10-K	0000950170-22-003145
20	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$36.1M	2019-12-31	2021-03-15	10-K	0001493152-21-006016
21	assets	us-gaap:Assets	\$28.3M	2023-12-31	2025-03-11	10-K	0000950170-25-037335
22	assets	us-gaap:Assets	\$66.3M	2022-12-31	2024-03-12	10-K	0000950170-24-030133
23	shares outstanding	dei:EntityCommonStockSharesOutstanding	17,736,464	2026-03-06	2026-03-09	10-K	0001193125-26-098530
24	shares outstanding	dei:EntityCommonStockSharesOutstanding	12,232,228	2025-03-07	2025-03-11	10-K	0000950170-25-037335